|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Lung and Thoracic cancer
Targeting CD73 to Overcomes Resistance to First-Generation EGFR
Tyrosine Kinase Inhibitor
s in Non–Small Cell Lung Cancer
Miso Kim, Soyeon Kim, Jeemin Yim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo
Cancer Res Treat.
2023;55(4):1134-1143. Published online May 23, 2023 DOI:
https://doi.org/10.4143/crt.2023.311
Hematologic malignancy
Clinical Impact of Drug Adherence of
Tyrosine Kinase Inhibitor
s in Children with Ph-Positive Acute Lymphoblastic Leukemia
Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu
Cancer Res Treat.
2023;55(3):1023-1030. Published online February 6, 2023 DOI:
https://doi.org/10.4143/crt.2022.1618
Lung and Thoracic cancer
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced
EGFR
-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Cancer Res Treat.
2023;55(3):841-850. Published online February 13, 2023 DOI:
https://doi.org/10.4143/crt.2022.1438
Crossref 2
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced
EGFR
-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Res Treat.
2022;54(2):434-444. Published online August 2, 2021 DOI:
https://doi.org/10.4143/crt.2021.671
Web of Science 6
Crossref 9
EGFR
C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with
EGFR
T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat.
2020;52(4):1288-1290. Published online June 22, 2020 DOI:
https://doi.org/10.4143/crt.2020.278
Web of Science 17
Crossref 7
Breast cancer
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu
Cancer Res Treat.
2020;52(4):1059-1066. Published online April 24, 2020 DOI:
https://doi.org/10.4143/crt.2019.633
Web of Science 29
Crossref 15
RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of
Tyrosine Kinase Inhibitor
s in Triple-Negative Breast Cancer
Tian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yao
Cancer Res Treat.
2020;52(3):973-986. Published online April 22, 2020 DOI:
https://doi.org/10.4143/crt.2019.726
Web of Science 14
Crossref 14
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
Cancer Res Treat.
2020;52(1):284-291. Published online July 23, 2019 DOI:
https://doi.org/10.4143/crt.2019.200
Web of Science 5
Crossref 4
Acquired Resistance of
MET
-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo
Cancer Res Treat.
2019;51(3):951-962. Published online October 10, 2018 DOI:
https://doi.org/10.4143/crt.2018.052
Web of Science 42
Crossref 41
Clinical Outcomes of
EGFR
Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat.
2019;51(2):623-631. Published online July 23, 2018 DOI:
https://doi.org/10.4143/crt.2018.151
Web of Science 40
Crossref 34
Impact of Pulmonary Tuberculosis on the
EGFR
Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee
Cancer Res Treat.
2019;51(1):158-168. Published online April 2, 2018 DOI:
https://doi.org/10.4143/crt.2018.084
Web of Science 15
Crossref 13
EGFR
Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR
Tyrosine Kinase Inhibitor
s
Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
Cancer Res Treat.
2018;50(3):908-916. Published online September 19, 2017 DOI:
https://doi.org/10.4143/crt.2017.378
Web of Science 31
Crossref 25
Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model
Pawel Chrom, Rafal Stec, Lubomir Bodnar, Cezary Szczylik
Cancer Res Treat.
2018;50(1):103-110. Published online March 3, 2017 DOI:
https://doi.org/10.4143/crt.2017.033
Web of Science 26
Crossref 27
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han
Cancer Res Treat.
2017;49(4):1001-1011. Published online January 13, 2017 DOI:
https://doi.org/10.4143/crt.2016.546
Web of Science 37
Crossref 33
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to
EGFR
Mutation Status
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee
Cancer Res Treat.
2017;49(4):981-989. Published online January 6, 2017 DOI:
https://doi.org/10.4143/crt.2016.522
Web of Science 12
Crossref 12
Clinical Characteristics and Continued Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitor
Administration in
EGFR
-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang
Cancer Res Treat.
2016;48(3):1110-1119. Published online January 6, 2016 DOI:
https://doi.org/10.4143/crt.2015.289
Web of Science 6
Crossref 7
The Effect of Chemoradiotherapy with SRC
Tyrosine Kinase Inhibitor
, PP2 and Temozolomide on Malignant Glioma Cells
In Vitro
and
In Vivo
Keun-Yong Eom, Bong Jun Cho, Eun Jung Choi, Jin-Ho Kim, Eui Kyu Chie, Hong-Gyun Wu, Il Han Kim, Sun Ha Paek, Jae-Sung Kim, In Ah Kim
Cancer Res Treat.
2016;48(2):687-697. Published online June 4, 2015 DOI:
https://doi.org/10.4143/crt.2014.320
Web of Science 25
Crossref 22
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
Jaemin Jo, Jung Ho Kim, Ji Young Kim, Changlim Hyun, Jiyoung Rhee, Jungmi Kwon, Sanghoon Han, Wookun Kim
Cancer Res Treat.
2016;48(1):393-397. Published online February 17, 2015 DOI:
https://doi.org/10.4143/crt.2014.209
A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib
Meral Gunaldi, Ismail Oguz Kara, Berna Bozkurt Duman, Cigdem Usul Afsar, Melek Ergin, Arbil Avci
Cancer Res Treat.
2014;46(4):411-414. Published online July 18, 2014 DOI:
https://doi.org/10.4143/crt.2013.093
Web of Science 3
Crossref 2
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitor
s
Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Cancer Res Treat.
2014;46(4):323-330. Published online July 14, 2014 DOI:
https://doi.org/10.4143/crt.2013.120
Web of Science 22
Crossref 18
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitor
Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim
Cancer Res Treat.
2013;45(2):79-85. Published online June 30, 2013 DOI:
https://doi.org/10.4143/crt.2013.45.2.79
Crossref 14
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
D. Nathan Kim, Taek-Keun Nam, Kevin S. Choe, Hak Choy
Cancer Res Treat.
2012;44(2):74-84. Published online June 30, 2012 DOI:
https://doi.org/10.4143/crt.2012.44.2.74
Crossref 5
Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
Kuikui Jiang, Ruoxi Hong, Wen Xia, Qianyi Lu, Liang Li, Jianhao Huang, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Fei Xu, Shusen Wang
Received June 25, 2023 Accepted October 10, 2023 Published online October 12, 2023
DOI:
https://doi.org/10.4143/crt.2023.786
[Epub ahead of print]
1
Journal Impact Factor 4.6